Zhejiang Yatai Pharmaceutical Co., Ltd.

002370

CNE100000MM5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
3.11 ^CNY	-4.31%		-4.60%	-27.51%

26/04	Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/03	Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index

June 22, 2020 at 09:30 am IST

Latest news about Zhejiang Yatai Pharmaceutical Co., Ltd.

Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Court Orders Bankruptcy Liquidation of Yatai Pharma Unit	19/23/19	MT
Yatai Pharma Unit Creditor Seeks Bankruptcy Liquidation	18/23/18	MT
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/22/29	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	29/22/29	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments	19/22/19	CI
Yatai Pharmaceutical's Shareholder Plans to Sell 7.27% Stake in the Company	11/22/11	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/21/26	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	27/21/27	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	28/21/28	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	26/21/26	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	27/20/27	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. signed a mediation agreement to acquire the remaining 49% stake in Wuhan Optics Valley Yatai Pharmaceutical Co., Ltd. from Hubei Science & Technology Investment Group Corporation Limited.	15/20/15	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	26/20/26	CI
Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index	22/20/22	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	29/20/29	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Omits Final Cash Dividend for 2019	17/20/17	CI
Zhejiang Yatai Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	28/20/28	CI

Chart Zhejiang Yatai Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Yatai Pharmaceutical Co., Ltd.

More charts

Zhejiang Yatai Pharmaceutical Co., Ltd. is a China-based company engaged in the manufacture and distribution of drugs. The Company's main business consists of the research, development, production and sales of chemical agents, chemical raw materials and diagnostic reagents, as well as the provision of pharmaceutical research and development outsourcing (CRO) services. The Companyâs chemical agents are classified as antibiotics and non-antibiotic drugs. Along with its subsidiaries, the Company provides preclinical research services, clinical research services and other advisory services. The Company distributes its products primarily in domestic markets and overseas markets.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG YATAI PHARMACEUTICAL CO., LTD.	-27.51%	273M
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals